CVS Health and UnitedHealth Group rank among the largest players in U.S. healthcare, yet they operate with distinctly different models. CVS combines a national retail pharmacy network, the Aetna insurance arm, and the Caremark pharmacy benefit manager. UNH pairs the nation’s largest health insurer with Optum, its expanding healthcare-services business. This comparison matters for investors looking to weigh an integrated retailer-insurer’s recovery against a diversified managed-care leader that is regaining margin ground. Examining their performance, positioning, and risks can clarify which approach fits the current environment best.
CVS Health breaks down into three segments: Health Care Benefits (Aetna), Health Services (Caremark PBM), and Pharmacy & Consumer Wellness. After a tough 2024 that included an earnings miss and a CEO change, the company has regained traction. In the latest quarter, adjusted EPS climbed roughly 14% year over year to $2.57, topping estimates, while revenue rose about 6% to near $100 billion. Management lifted full-year 2026 adjusted EPS guidance to a range of $7.30 to $7.50. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Aetna drove much of the improvement, with the medical benefit ratio falling to 84.6% from 87.3% a year earlier, reflecting better cost discipline. Recent developments include an FTC settlement on Caremark’s payment model and a move toward biosimilars. These factors have helped shares approach a 52-week high, though Medicare Advantage margins and pharmacy reimbursement pressures remain key risks.
UnitedHealth Group operates UnitedHealthcare, the largest U.S. health insurer, together with Optum, which covers pharmacy services, care delivery, and data and technology. Following a difficult 2025 shaped by higher medical costs and regulatory attention, the company has posted a clearer earnings rebound. Adjusted EPS jumped about 61% year over year to $4.69 in the most recent quarter, beating expectations, while revenue eased slightly to roughly $113 billion. Management raised its 2026 adjusted EPS outlook to at least $20.50. The medical care ratio improved to 88.4% from 89.9% a year earlier. From what I see, the firm has deliberately allowed membership to decline to about 48.3 million as it favors profitable growth, especially in Medicare Advantage. Optum’s services turnaround has added support. A recent note that Berkshire Hathaway exited its stake, along with ongoing commercial-cost pressures, has kept sentiment measured.
On business model, CVS is an integrated healthcare conglomerate whose results depend on Aetna’s turnaround plus managing PBM regulatory changes and a lower-margin retail pharmacy operation. UNH is a managed-care leader diversified into Optum, which provides more balanced revenue streams but also broad exposure to insurance utilization trends. On scale, UNH is larger, with full-year revenue expected near $450 billion compared with CVS guidance of at least $405 billion. Both stocks have outperformed recently, though through different drivers. CVS gains stem from insurance-margin recovery and guidance increases after earlier underperformance, while UNH reflects a return to earnings growth even as membership contracts. On risk, CVS faces greater pharmacy reimbursement and PBM regulatory exposure, whereas UNH contends with commercial medical-cost trends and legal scrutiny. Analyst estimate revisions have trended higher for both, though UNH trades at a richer valuation multiple relative to its peers.
I have found Tickeron’s Trending AI Robots page useful when comparing names like these. It highlights automated strategies that fit current market conditions, each with its own style, timeframe, and documented performance metrics. Reviewing the selection helps put the relative momentum of CVS and UNH into perspective without replacing deeper fundamental work.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
It is expected that a price bounce should occur soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +1.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where UNH advanced for three days, in 187 of 331 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
UNH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UNH as a result. In 56 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.
The Moving Average Convergence Divergence Histogram (MACD) for UNH turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 27 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 59%.
UNH moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for UNH crossed bearishly below the 50-day moving average on November 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UNH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.
The Aroon Indicator for UNH entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. UNH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.594) is normal, around the industry mean (3.520). P/E Ratio (25.266) is within average values for comparable stocks, (126.353). Projected Growth (PEG Ratio) (1.025) is also within normal values, averaging (0.786). UNH has a moderately high Dividend Yield (0.024) as compared to the industry average of (0.009). P/S Ratio (0.757) is also within normal values, averaging (0.569).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UNH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of hospital and medical service plans
Industry ManagedHealthCare